1. Home
  2. INTG vs EQ Comparison

INTG vs EQ Comparison

Compare INTG & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intergroup Corporation (The)

INTG

Intergroup Corporation (The)

N/A

Current Price

$37.10

Market Cap

59.3M

Sector

Real Estate

ML Signal

N/A

EQ

Equillium Inc.

HOLD

Current Price

$2.13

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INTG
EQ
Founded
1965
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Building operators
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
59.3M
64.5M
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
INTG
EQ
Price
$37.10
$2.13
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$6.50
AVG Volume (30 Days)
5.4K
552.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
39.47
EPS
0.46
N/A
Revenue
$74,753,000.00
$41,095,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$84.39
N/A
Revenue Growth
4.43
13.89
52 Week Low
$10.37
$0.29
52 Week High
$42.50
$2.70

Technical Indicators

Market Signals
Indicator
INTG
EQ
Relative Strength Index (RSI) 63.45 58.06
Support Level $25.16 $1.22
Resistance Level $37.75 $2.30
Average True Range (ATR) 1.71 0.23
MACD 0.45 0.02
Stochastic Oscillator 79.74 41.06

Price Performance

Historical Comparison
INTG
EQ

About INTG Intergroup Corporation (The)

The Intergroup Corp is a company operating in the real estate sector. It was formed to buy, develop, operate, rehabilitate, and dispose of real property of various types and descriptions, as well as to engage in other related business and investment activities. The company operates through three segments: Hotel, Real Estate, and Investment Transactions. The Hotel Operations segment, which generates the majority of the revenue, covers the operation of the Hilton hotel and garage. The Real Estate Operations segment involves the management of multifamily rental properties, while the Investment Transactions segment includes investments of cash in marketable securities and other assets.

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: